TY - JOUR
T1 - Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease
T2 - results from the INTERASPIRE study in seven countries across five World Health Organization regions
AU - Jennings, Catriona Sian
AU - Kenny, Eanna
AU - De Bacquer, Dirk
AU - Cegla, Jaimini
AU - Ray, Kausik Kumar
AU - Corry, John-Paul
AU - Adamska, Agnieszka
AU - Kotseva, Kornelia
AU - McEvoy, John W
AU - Noone, Chris
AU - Ganly, Sandra
AU - Alali, Juwairia
AU - Al Mahmeed, Wael
AU - Bazargani, Nooshin
AU - Ge, Junbo
AU - Hui-Chin Jong, Rose
AU - Hui-Ping Foo, Diana
AU - Huo, Yong
AU - Luna Bonilla, Paula
AU - Ji, Nancy Xinrong
AU - Jankowski, Piotr
AU - Li, Yong
AU - Mbakwem, Amam
AU - Mbau, Lilian Kagure
AU - Ogah, Okechukwu Samuel
AU - Ogola, Elijah N
AU - Quintero-Baiz, Adalberto Elias
AU - Sani, Mahmoud Umar
AU - Urina-Triana, Miguel A
AU - Wolfshaut-Wolak, Renata
AU - Zuhdi, Ahmad Syadi Mahmood
AU - Wood, David Allan
N1 - © The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
PY - 2025/8/29
Y1 - 2025/8/29
N2 - AIMS: Lipoprotein(a) [Lp(a)], an inherited lipoprotein, was measured in patients with coronary disease participating in the INTERASPIRE study. The aim of this study was to survey patients' knowledge and perceptions of cardiovascular risk and their views on Lp(a) testing, consequences, and treatment.METHODS AND RESULTS: In seven participating countries, recruited patients were divided into those with elevated Lp(a) [≥ 50 mg/dL (≥115 mmol/L)] and those with normal levels. In the elevated group, patients were given an educational leaflet about Lp(a), advised to see their physician and subsequently attended a telephone interview that included study-specific questionnaires assessing knowledge, risk perception, and interest in and acceptability of Lp(a) testing. A random sample of patients with normal Lp(a) were interviewed in the same way. Eight hundred fifty-six patients were interviewed, 523 (22.6% female) with normal Lp(a) and 333 (29.1% female) with elevated Lp(a). Knowledge of cardiovascular disease (CVD) was similar in both groups with a score of 62.1% in normal Lp(a) and 59.6 in elevated Lp(a) P = 0.073. Knowledge of Lp(a) and its management in both groups was poor. Patients with elevated Lp(a) were worried by their result but found testing acceptable and appreciated the benefits. They were motivated to reduce their risk of CVD despite the absence of medical therapies and were eager to receive advice.CONCLUSION: Health professionals working in CVD care should be aware of the need to investigate patients with coronary disease for Lp(a) and be equipped to give advice on how to reduce overall cardiovascular risk especially given the absence of licenced therapies to treat Lp(a).
AB - AIMS: Lipoprotein(a) [Lp(a)], an inherited lipoprotein, was measured in patients with coronary disease participating in the INTERASPIRE study. The aim of this study was to survey patients' knowledge and perceptions of cardiovascular risk and their views on Lp(a) testing, consequences, and treatment.METHODS AND RESULTS: In seven participating countries, recruited patients were divided into those with elevated Lp(a) [≥ 50 mg/dL (≥115 mmol/L)] and those with normal levels. In the elevated group, patients were given an educational leaflet about Lp(a), advised to see their physician and subsequently attended a telephone interview that included study-specific questionnaires assessing knowledge, risk perception, and interest in and acceptability of Lp(a) testing. A random sample of patients with normal Lp(a) were interviewed in the same way. Eight hundred fifty-six patients were interviewed, 523 (22.6% female) with normal Lp(a) and 333 (29.1% female) with elevated Lp(a). Knowledge of cardiovascular disease (CVD) was similar in both groups with a score of 62.1% in normal Lp(a) and 59.6 in elevated Lp(a) P = 0.073. Knowledge of Lp(a) and its management in both groups was poor. Patients with elevated Lp(a) were worried by their result but found testing acceptable and appreciated the benefits. They were motivated to reduce their risk of CVD despite the absence of medical therapies and were eager to receive advice.CONCLUSION: Health professionals working in CVD care should be aware of the need to investigate patients with coronary disease for Lp(a) and be equipped to give advice on how to reduce overall cardiovascular risk especially given the absence of licenced therapies to treat Lp(a).
U2 - 10.1093/eurjcn/zvaf174
DO - 10.1093/eurjcn/zvaf174
M3 - Article
C2 - 40879469
SN - 1474-5151
JO - European Journal of Cardiovascular Nursing
JF - European Journal of Cardiovascular Nursing
ER -
SDG 3 Good Health and Well-being